Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Leuk Lymphoma. 2020 May 2;61(9):2180–2190. doi: 10.1080/10428194.2020.1759051

Figure 2: Kaplan-Meier survival estimates by transplant recipient status.

Figure 2:

Figure 2 shows Kaplan-Meier survival curves for patients who proceeded to alloHSCT (n=11 patients) and those who did not (n=72 patients). In a stratified Cox proportional hazards model, patients who received alloHSCT had a significant survival benefit compared to non-transplant patients (median OS: not reached [95% CI: 6.6 months – not reached] vs 6 months [95% CI: 2.9 −8.8 months]; hazard ratio: 0.08; p = 0.002)